Kennon Heard1, Jody L Green2, Victoria Anderson2, Becki Bucher-Bartelson2,3, Richard C Dart1,2. 1. Department of Emergency Medicine, University of Colorado School of Medicine, Denver, CO, USA. 2. Rocky Mountain Poison and Drug Center, Denver Health, Denver, CO, USA. 3. Colorado School of Public Health, Aurora, CO, USA.
Abstract
BACKGROUND:Paracetamol protein adducts (PPA) are a biomarker of paracetamol exposure. PPA are quantified as paracetamol-cysteine (APAP-CYS), and concentrations above 1.1 μmol l(-1) have been suggested as a marker of paracetamol-induced hepatotoxicity. However, there is little information on the range of concentrations observed during prolonged therapeutic dosing. AIM: The aim of the present study was to describe the concentration of PPA in the serum of subjects taking therapeutic doses of paracetamol for at least 16 days. METHODS: Preplanned secondary aim of a prospective randomized controlled (placebo vs. 4g day(-1) paracetamol) trial. We measured subjects' serum PPA concentrations every 3 days for a minimum of 16 days. We also measured concentrations on study days 1-3 and 16-25 in subsets of patients. PPA were quantified as APAP-CYS after gel filtration and protein digestion using liquid chromatography/mass spectrometry. RESULTS: Ninety per cent of subjects had detectable PPA after five doses. Median APAP-CYS concentrations in paracetamol-treated subjects increased to a plateau of 0.1 μmol l(-1) on day 7, where they remained. The highest concentration measured was 1.1 μmol l(-1) and two subjects never had detectable PPA levels. PPA were detected in the serum of 78% of subjects 9 days after their final dose. CONCLUSIONS:PPA are detectable in the vast majority of subjects taking therapeutic doses of paracetamol. While most have concentrations well below the threshold associated with hepatotoxicity, concentrations may approach 1.1 μmol l(-1) in rare cases. Adducts are detectable after a few doses and can persist for over a week after dosing is stopped.
RCT Entities:
BACKGROUND:Paracetamol protein adducts (PPA) are a biomarker of paracetamol exposure. PPA are quantified as paracetamol-cysteine (APAP-CYS), and concentrations above 1.1 μmol l(-1) have been suggested as a marker of paracetamol-induced hepatotoxicity. However, there is little information on the range of concentrations observed during prolonged therapeutic dosing. AIM: The aim of the present study was to describe the concentration of PPA in the serum of subjects taking therapeutic doses of paracetamol for at least 16 days. METHODS: Preplanned secondary aim of a prospective randomized controlled (placebo vs. 4g day(-1) paracetamol) trial. We measured subjects' serum PPA concentrations every 3 days for a minimum of 16 days. We also measured concentrations on study days 1-3 and 16-25 in subsets of patients. PPA were quantified as APAP-CYS after gel filtration and protein digestion using liquid chromatography/mass spectrometry. RESULTS: Ninety per cent of subjects had detectable PPA after five doses. Median APAP-CYS concentrations in paracetamol-treated subjects increased to a plateau of 0.1 μmol l(-1) on day 7, where they remained. The highest concentration measured was 1.1 μmol l(-1) and two subjects never had detectable PPA levels. PPA were detected in the serum of 78% of subjects 9 days after their final dose. CONCLUSIONS:PPA are detectable in the vast majority of subjects taking therapeutic doses of paracetamol. While most have concentrations well below the threshold associated with hepatotoxicity, concentrations may approach 1.1 μmol l(-1) in rare cases. Adducts are detectable after a few doses and can persist for over a week after dosing is stopped.
Authors: Kenneth L Muldrew; Laura P James; Leslie Coop; Sandra S McCullough; Howard P Hendrickson; Jack A Hinson; Philip R Mayeux Journal: Drug Metab Dispos Date: 2002-04 Impact factor: 3.922
Authors: Sarah F Cook; Amber D King; Yan Chang; Gordon J Murray; Hye-Ryun K Norris; Richard C Dart; Jody L Green; Steven C Curry; Douglas E Rollins; Diana G Wilkins Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2015-01-24 Impact factor: 3.205
Authors: Laura P James; Estella M Alonso; Linda S Hynan; Jack A Hinson; Timothy J Davern; William M Lee; Robert H Squires Journal: Pediatrics Date: 2006-09 Impact factor: 7.124
Authors: Timothy J Davern; Laura P James; Jack A Hinson; Julie Polson; Anne M Larson; Robert J Fontana; Ezmina Lalani; Santiago Munoz; A Obaid Shakil; William M Lee Journal: Gastroenterology Date: 2006-03 Impact factor: 22.682
Authors: L P James; E V Capparelli; P M Simpson; L Letzig; D Roberts; J A Hinson; G L Kearns; J L Blumer; J E Sullivan Journal: Clin Pharmacol Ther Date: 2008-10-15 Impact factor: 6.875
Authors: Laura P James; Lynda Letzig; Pippa M Simpson; Edmund Capparelli; Dean W Roberts; Jack A Hinson; Timothy J Davern; William M Lee Journal: Drug Metab Dispos Date: 2009-05-13 Impact factor: 3.922
Authors: Petra Thulin; Gunnar Nordahl; Marcus Gry; Getnet Yimer; Eleni Aklillu; Eyasu Makonnen; Getachew Aderaye; Lars Lindquist; C Mikael Mattsson; Björn Ekblom; Daniel J Antoine; B Kevin Park; Stig Linder; Alison H Harrill; Paul B Watkins; Björn Glinghammar; Ina Schuppe-Koistinen Journal: Liver Int Date: 2013-10-14 Impact factor: 5.828
Authors: Luqi Duan; Anup Ramachandran; Jephte Y Akakpo; James L Weemhoff; Steven C Curry; Hartmut Jaeschke Journal: Toxicol Lett Date: 2018-11-15 Impact factor: 4.372
Authors: Sibo Jiang; Valvanera Vozmediano; Susan M Abdel-Rahman; Stephan Schmidt; Laura P James Journal: J Clin Pharmacol Date: 2019-05-17 Impact factor: 3.126